Urothelial Carcinoma | Norton Healthcare

Indication: Urothelial Carcinoma

A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy

Untreated locally advanced or metastatic

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: F. Hoffmann-LaRoche Ltd.

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.